About 28% of patients potentially eligible for immune checkpoint inhibitors when assessed with the following biomarkers: high tumor mutational load (46 of 389 patients [11.8%]), high microsatellite instability (7 of 389 [1.8%]), and PD‐L1 expression (82 of 365 patients [22.5%]). Here, CD274 is linked to neoplasm.